Apoptotic effect of was not enhanced by co-treatment with myo-inositol in prostate carcinoma PC3 cells |
Kim, Hyun-Jung
(Department of Food and Nutrition, Seoul National University)
Jang, Yu-Mi (Department of Food and Nutrition, Seoul National University) Kim, Harriet (Department of Food and Nutrition, Seoul National University) Kwon, Young-Hye (Research Institute of Human Ecology, Seoul National University) |
1 | Estensen R & Wattenberg L (1993). Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 14: 1975-1977 DOI ScienceOn |
2 | Grases F, Simonet B, Vucenik I, Perello J, RM P & Shamsuddin A (2002). Effects of exogenous inositol hexakisphosphate (InsP(6)) on the levels of InsP(6) and of inositol trisphosphate (InsP(3)) in malignant cells, tissues and biological fluids. Life Sci 71: 1535-1546 DOI ScienceOn |
3 | Singh RP, Sharma G, Mallikarjuna G, Dhanalakshm S, Agarwal C & Agarwal R (2004). In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res 10:244-250 DOI ScienceOn |
4 | Venkateswaran V, Klotz LH & Fleshner NE (2002). Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 62:2540-2545 |
5 | Vucenik I, Tantivejkul K, Zhang Z, Cole K, Saied I & Shamsuddin A (1998a). IP6 in treatment of liver cancer. I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 18:4083-4090 |
6 | Shamsuddin A (1999). Metabolism and cellular functions of IP6: a review. Anticancer Res 19:3733-3736 |
7 | Shamsuddin A, Yang G & Vucenik I (1996). Novel anti-cancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res 16:3287-3292 |
8 | Vucenik I, Zhang Z & Shamsuddin A (1998b). IP6 in treatment of liver cancer. II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res 18:4091-4096 |
9 | Shamsuddin A, Ullah A & Chakravarthy A (1989). Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice. Carcinogenesis 10:1461-1463 DOI ScienceOn |
10 | Isaacs W, Carter B & Ewing C (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720 |
11 | Vucenik I & Shamsuddin A (2003). Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 133:3778S-3784S DOI |
12 | Ferry S, Matsuda M, Yoshida H & Hirata M (2002). Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkB-mediated cell survival pathway. Carcinogenesis 23:2031-2041 DOI ScienceOn |
13 | Vucenik I, Yang G & Shamsuddin A (1995). Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. Carcinogenesis 16:1055-1058 DOI ScienceOn |
14 | Diallo JS, Peant B, Lessard L, Delvoye N, Le Page C, Mes-Masson AM & Saad F (2006). An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. Prostate 66:1245-1256 DOI ScienceOn |
15 | Agarwal C, Dhanalakshmi S, Singh R & Agarwal R (2004). Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia 6:646-659 DOI ScienceOn |
16 | Morgan DO (1995). Principles of CDK regulation. Nature 974: 131-134 |
17 | Singh RP, Agarwal C & Agarwal R (2003). Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRB-related protein-E2F complexes. Carcinogenesis 24:555-563 DOI ScienceOn |
18 | Razzini G, Berrie C, Vignati S, Broggini M, Mascetta G, Brancaccio A & Falasca M (2000). Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J 14:1179-1187 DOI |
19 | Zi X, Singh R & Agarwal R (2000). Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 21:2225-2235 DOI ScienceOn |
20 | Shamsuddin A, Vucenik I & Cole K (1997). IP6: A novel anti-cancer agent. Life Sci 61:343-354 DOI ScienceOn |
21 | Sasakawa N, Sharif M & Hanley M (1995). Metabolism and biological activities of inositol pentakisphosphate and inositol hexakisphosphate. Biochem Pharmacol 50:137-146 DOI ScienceOn |
22 | Reddy N, Sathe S & Salunkhe D (1982). Phytates in legumes and cereals. Adv Food Res 28:1-92 |
23 | Vucenik I, Ramakrishna G, Tantivejkul K, Anderson L & Ramljak D (2005). Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res Treat 91:35-45 DOI ScienceOn |
24 | Sakamoto K, Venkatraman G & Shamsuddin A (1993). Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). Carcinogenesis 14:1815-1819 DOI ScienceOn |